Chiadikaobi Onyike, MD
Psychiatry · Baltimore, MDNPI 1184678724
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $40,563 of the $53,998 with a category attached, or 75.1%. 9 manufacturers reported payments, led by Eli Lilly at 24.7% of the total. Reporting peaked in 2024 at $25,307 and has fallen 95.6% since, to $1,102 in 2025. Among psychiatry clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 25 payments — averaging $2159.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$13K
- Zevra Therapeutics Inc$12K
- Eisai Inc.$12K
- H. Lundbeck A S$11K
- Acadia Pharmaceuticals Inc$5K
- Sanofi US Services Inc.$1K
- plus $367 from 3 others
Across 14 payments — averaging $2694.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$29K
- Johnson & Johnson$8K
- Janssen Research & Development, LLC$900
What the payments were for
- Consulting fees$40,56375%
- Speaking & faculty fees$10,80020%
- Travel & lodging$1,7433%
- Food & beverage$8922%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 11 | $13,312 |
| Zevra Therapeutics Inc | 1 | $11,700 |
| Eisai Inc. | 1 | $11,500 |
| H. Lundbeck A S | 1 | $10,800 |
| Acadia Pharmaceuticals Inc | 2 | $5,289 |
| Sanofi US Services Inc. | 5 | $1,030 |
| Viiv Healthcare Company | 2 | $211 |
| AstraZeneca | 1 | $83 |
| Axsome Therapeutics, Inc. | 1 | $72 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$53,998 in reported general payments places this provider in the 95th percentile of 851 psychiatry providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyvanseLisdexamfetamine Dimesylate | 14 | $6,946 |
| Rivastigmine | 12 | $2,278 |
| AmantadineAmantadine Hcl | 24 | $1,027 |
| Olanzapine | 27 | $838 |
| Memantine Hcl | 22 | $719 |
| Quetiapine Fumarate | 20 | $509 |
| Fluphenazine Hcl | 14 | $466 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 11 | $399 |
| Lithium Carbonate ErLithium Carbonate | 13 | $228 |
| Sertraline Hcl | 38 | $186 |
| Trazodone Hcl | 19 | $173 |
| Risperidone | 23 | $165 |
| Escitalopram Oxalate | 15 | $135 |
| Citalopram HbrCitalopram Hydrobromide | 19 | $131 |
| Donepezil Hcl | 22 | $114 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Baltimore
- John VaethBaltimore$2.1M
- Scott AaronsonBaltimore$334K
- Robert LehmanBaltimore$140K
- Karen AndersonBaltimore$117K
- Orlando DavisBaltimore$104K
- Akira SawaBaltimore$69K
- Paul RosenbergBaltimore$66K
- Adam KaplinBaltimore$62K
- Marc FishmanBaltimore$59K
- David NeubauerBaltimore$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.